Venture capital is increasingly becoming the growing force for financing biotech and other startups, fueling medical advances in the U.S. A new report released today from TEConomy, examines the role and impact of one specific player in that ecosystem: biopharmaceutical corporate venture capital (CVC) funds, which often support early stage medical innovation.
A growing number of biopharmaceutical companies have affiliated CVC funds which provide direct investments in young, innovative and highly risky companies. These biopharma CVC funds not only provide direct investments to promising startups but also mentoring, strategic guidance and other support.
The report identified and reviewed trends related to CVC funds affiliated with PhRMA member companies —generally quasi- or fully independent venture capital groups. TEConomy found that deals involving PhRMA member CVC investments grew from just $414 million in 2000 to $3.2 billion in 2017. These CVC funds offer funding at critical points in an emerging company’s evolution, while also offering non-financial support that can help give startups a competitive edge.
The report also shows that biopharmaceutical CVC funds are active in early stage investments, even when traditional VC partners have shied away from such deals. For example, in 2011, 73 percent of PhRMA member CVC investments were in early stage deals while just 48 percent of deals made by traditional VC firms were to support early stage research.
The report further found that CVC investments are helping sustain the health of the early stage biomedical ecosystem when it can be most risky. The areas of investment are broad and characterized by a high degree of innovation and uncertainty. A key area of investment is new digital health technologies that can improve health care delivery. These can include mobile health applications to provide patients with reminders and other information to manage their health care condition, and the use of health information technologies to integrate lab, clinical and other data to support medical decision making.
Other research has found that CVC backed companies have a higher rate of overall success than those without their involvement. PhRMA member CVC funds do not just provide financial support but also access to highly skilled R&D experts, strategic guidance through board participation or informal consultations on manufacturing, regulatory and other critical aspects of biomedical innovation. In addition, PhRMA member CVC funds can offer access to lab space and other key infrastructure. This additional support has helped generate a higher share of initial public offerings by biotech startups backed by PhRMA member CVC funds than those without such support.
Biopharma CVC funds are just one more way in which PhRMA member companies are seeking to sustain and grow the vibrant U.S. R&D biopharmaceutical ecosystem that continues to lead the world in medical innovation, bringing new medical advances to patients.
To learn more about the role corporate venture capital has in the biopharmaceutical research and development process, click here.
Guest Contributor
The PhRMA blog welcomes guest contributors, including patients, stakeholders, innovators and others, to share their perspectives and point of view on issues facing our industry and the health care system.
Guest Contributor
Staffing up: Building the future biopharma workforce to keep America in the lead
Nearly 80 researchers advocate on Capitol Hill
Congratulations to our 2026 Working for Cures Employee Champions
Manufacturing U.S. jobs and breakthroughs
Historic biopharmaceutical investments: A prescription for America’s future
Bringing to life the full story of biopharmaceutical innovation and investments
From sound to science: How IP powers innovation in music and hearing
Recognizing the value of disease prevention with Dr. Len Friedland from GSK
Congratulations to our 2024 Working for Cures Employee Champions
The importance of partnership: A conversation with Takeda
New research: American biopharmaceutical investment in R&D drives transformational innovation
The future of oncology R&D lies in policymakers’ hands
More than 60 researchers advocate on Capitol Hill
Alzheimer's & Brain Awareness Month: A conversation with Biogen
Alzheimer's & Brain Awareness Month: A conversation with Eisai
Alzheimer's & Brain Awareness Month: A conversation with Eli Lilly and Company
Powering the next generation of therapies: A conversation with Astellas US President Mark Reisenauer
Congratulations to our 2023 Working for Cures Employee Champions
Watch: Putting patients front and center for World AIDS Day
New Report: 1,600 cancer treatments and vaccines in clinical development
Incomplete evaluations undermine patient access to transformational medicine
Watch: New video series spotlights advances in biopharmaceutical science
New report shows high-impact R&D happens after cancer medicines are first approved
More than 60 researchers ask Congress to support innovation
Biopharmaceutical science powered by PRIDE
Addressing Mental Health: A conversation with Barry Greene, CEO of Sage Therapeutics
World IP Day 2023: Celebrating women leaders in innovation
What we’ve learned from three years of fighting COVID-19
WTAS: Inflation Reduction Act already impacting R&D decisions
Sparking conversations — and careers — at the 2nd annual Pathways to Success Summit
Stories from the lab: Researchers discuss innovative treatments for cancers of the blood
Congratulations to our 2022 Working for Cures Employee Champions
Protecting against influenza: A conversation with David Ross, Vice President, Commercial Operations, North America, CSL Seqirus
An open letter to Congress: Stand with patients and future cures
PhRMA member companies’ R&D investments reach record high of $102.3 billion in 2021
Biopharmaceutical researchers to discuss the value of R&D with Congress
A conversation with Barry Greene, CEO of Sage Therapeutics
Innovative contracts continue to gain traction and improve quality of care
Stephanie Dyson of BMS on reducing health disparities
Biopharmaceutical industry drives economic growth in all 50 states
Guest post: Joining forces to combat the COVID-19 mental health crisis
Upcoming graduate student summit will showcase pathways to success within the biopharmaceutical industry
Guest Series: PhRMA talks racial and health equity with Lauren Powell, VP US Health Equity and Community Wellness, Takeda
Industry leaders discuss the impact of the drug pricing debate
PhRMA member companies’ R&D investments reach record high of $91.1 billion in 2020
Watch: Building trust and enhancing clinical trial diversity
Building a better health care system: A conversation with Mark Reisenauer, President of Astellas US
Researchers to shine light on biopharmaceutical R&D with policymakers
Key takeaways: PhRMA comments to USPTO on how to make the innovation ecosystem more diverse and inclusive
Coming together to fight COVID-19: A conversation with Paul Perreault, CEO and Managing Director of CSL
Guest post: PhRMA talks racial and health equity with Stephanie Dyson, Head of Office at Biogen
Report highlights biopharmaceutical industry’s commitment to D&I
Guest Post: Bringing our best to the fight against COVID-19
An unprecedented year and the road ahead: A conversation with Giovanni Caforio, PhRMA Chairman and CEO of Bristol Myers Squibb
Coming together to fight COVID-19: A conversation with Peter Anastasiou, Executive Vice President of Lundbeck
New Report: The biopharmaceutical industry’s sustained commitment to inspiring and advancing tomorrow’s STEM workforce
Coming together to fight COVID-19: A conversation with Alexander Hardy, CEO of Genentech
Leading researchers to spotlight the critical role of biopharmaceutical R&D
Growth in innovative, value-based contracts holds promise for the health system and for patients
Coming together to fight COVID-19: A conversation with Ramona Sequeira, President of Takeda Pharmaceuticals U.S.A
Coming together to fight COVID-19: A conversation with Albert Bourla, Chairman & CEO of Pfizer, Inc.
Guest Post: How proactivity and planning helped Novartis ensure a stable supply of medicines during COVID-19
PhRMA member companies invested $83 billion in research and development last year
Coming together to fight COVID-19: A conversation with Paul Hudson, CEO of Sanofi
Three ways the pharmaceutical industry can positively impact health equity
ICYMI: The latest as America’s biopharmaceutical companies work to beat COVID-19
New report explores setbacks that bring future cancer success stories
In combating COVID-19, science is how we get back to normal
Guest Post: Takeda seeks ‘new normal’ for cancer research during the COVID-19 pandemic
Guest Post: What will we learn from COVID-19?
Lilly, Merck and Pfizer empower team members to volunteer on COVID-19 frontlines
To the millions affected by COVID-19
Merck’s Dr. Julie Gerberding on the threat of antimicrobial resistance and COVID-19
The biopharmaceutical industry’s unique role in responding to COVID-19
ICYMI: America’s biopharmaceutical companies are working 'around the clock' to beat coronavirus
COVID-19 Response: Supporting the frontline
Guest post: Looking out for the invisibly vulnerable in the time of COVID-19
America’s biopharmaceutical companies are working around the clock to beat coronavirus
Guest post: Takeda’s efforts to address COVID-19
ICYMI: America’s biopharmaceutical companies are taking on COVID-19
ICYMI: Continued biopharmaceutical action on COVID-19
Working together to combat coronavirus
Guest post: Value-based agreements can improve outcomes and even save patients money at the pharmacy counter
New data show how ICER’s value framework could prevent or delay access to treatments for Medicaid patients across the country
5 Ways to improve ICER’s value assessment framework
Assessing value top of mind at ISPOR 2019
Event tomorrow: Leaders convene to discuss solutions to advance value-driven health care
New whitepaper identifies reasons why ICER’s cost-effectiveness analyses are not useful for payers
Guest post: Developing new payment models to ensure patients have access to high-investment therapies
Number of value-based contracts continues to rise
ICER’s budget impact threshold: Sounding a false alarm on affordability and access
PhRMA submission to HHS on blueprint to lower drug prices and reduce out-of-pocket costs
How ICER’s assessment of a new class of migraine treatments fails patients
Aspen Spotlight Health: Discussing the forefront of innovation
New analysis shows that HTA organizations may frequently restrict access to cancer treatments
New analysis shows negative impact of ICER’s value framework on patient access in Medicare Part B
ICYMI: Recent survey adds to growing body of research on barriers to innovative payment approaches
Event tomorrow: Improving patient access to lifesaving medicines
Reality check: Value-based contracts are good for patients
Video: Barriers to results-based contracts
Improving care quality by engaging patients in shared decision making
ICYMI: Research shows promise of innovative payment arrangements in reducing costs, improving access
Clarity around anti-kickback statute needed to promote innovative payment arrangements
Video: What is a results-based contract?
PhRMA Foundation recognizes inaugural Challenge Award recipients
Helping those affected by the 2017 hurricane season
Medicare Monday: How Part B has evolved over the years
Modernizing FDA regulations to advance a value-driven health care system
Celebrating PRIDE in biopharmaceutical science
ICYMI: Avalere and FasterCures develop new value framework from patient perspective
RA medicines often demonstrate far greater benefits to patients than initially understood
New analysis: More than half of patients’ out-of-pocket spending for brand medicines is based on full list price
Guest Post: The importance of a modern FDA in drug discovery
Stakeholders Agree: Modernize the legal framework to support move to value-driven health care
How do multiple sclerosis patients define value?
Exploring the new era of medicine
Guest Post: Johnson and Johnson is celebrating outstanding scientists: Who will be next?
Watch: Biomarkers in drug development with Dr. Bernie Zeiher
PhRMA CEO talks White House meeting, innovation & jobs with POLITICO’s Pulse Check
VIDEO: PhRMA CEO discusses #GOBOLDLY campaign and White House meeting with CNNMoney’s Maggie Lake
The Value Collaborative: Advancing private market solutions to achieve better health, lower costs
The journey to better health care requires a holistic view
PhRMA Member Company
Value-Driven Health Care
The journey to better health care requires a holistic view
The journey to better health care requires a holistic view